about
Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.Darunavir: an effective protease inhibitor for HIV-infected patients.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.HIV protease inhibitors in pregnancy : pharmacology and clinical use.
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Use of darunavir and enfuvirtide in a pregnant woman.
@en
Use of darunavir and enfuvirtide in a pregnant woman.
@nl
type
label
Use of darunavir and enfuvirtide in a pregnant woman.
@en
Use of darunavir and enfuvirtide in a pregnant woman.
@nl
prefLabel
Use of darunavir and enfuvirtide in a pregnant woman.
@en
Use of darunavir and enfuvirtide in a pregnant woman.
@nl
P2093
P2860
P356
P1476
Use of darunavir and enfuvirtide in a pregnant woman.
@en
P2093
A Krolewiecki
L Abusamra
P Patterson
P2860
P304
P356
10.1258/IJSA.2008.008075
P50
P577
2008-12-01T00:00:00Z